SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Option exercise | 2817 | $235K |
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Open-market sell | 2817 | $960K |
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Option exercise | 2818 | $235K |
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Open-market sell | 2818 | $960K |
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Option exercise | 2500 | $224K |
| Favorite Annette F | Sr. VP & Chief HR Officer | 2026-09-08 | Open-market sell | 2500 | $852K |
| McMahon Robert W. | SVP & Chief Financial Officer | 2026-08-11 | Option exercise | 794 | — |
| McMahon Robert W. | SVP & Chief Financial Officer | 2026-08-11 | Tax withholding | 346 | $121K |
| McMahon Robert W. | SVP & Chief Financial Officer | 2026-08-11 | Option exercise | 6355 | — |
| McMahon Robert W. | SVP & Chief Financial Officer | 2026-08-11 | Tax withholding | 2764 | $971K |
| Campbell Shane Alden | SVP, Proprietary Segment | 2026-05-12 | Option exercise | 296 | — |
| Campbell Shane Alden | SVP, Proprietary Segment | 2026-05-12 | Tax withholding | 84 | $26K |
| Campbell Shane Alden | SVP, Proprietary Segment | 2026-05-12 | Option exercise | 474 | — |
| Campbell Shane Alden | SVP, Proprietary Segment | 2026-05-12 | Tax withholding | 135 | $42K |
| BUTHMAN MARK A | Director | 2026-05-04 | Grant/award | 791 | $0 |
| FRIEL ROBERT F | Director | 2026-05-04 | Grant/award | 791 | $0 |
| Feehery William F | Director | 2026-05-04 | Grant/award | 791 | $0 |
| HAUGEN JANET BRUTSCHEA | Director | 2026-05-04 | Grant/award | 791 | $0 |
| Joseph Molly | Director | 2026-05-04 | Grant/award | 791 | $0 |
| Keller Deborah L | Director | 2026-05-04 | Grant/award | 791 | $0 |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Risk disclosures broadened materially across five distinct themes, with no offsetting easings. The most consequential additions are a concrete divestiture transaction (SmartDose to AbbVie) carrying operational and financial execution risk, newly identified PFAS regulatory exposure requiring potential product reformulation, and a specific GLP-1/oral-delivery competitive threat in a high-growth segment — together signaling a more complex and pressured operating environment than the prior year's disclosures suggested.
4 company-specific · 1 common-mode
New disclosure of active divestiture (SmartDose sale to AbbVie) and ongoing M&A strategy. Concrete transaction risk with material operational and financial consequences.
We may not succeed in completing divestitures, acquisitions or other strategic transactions, all of which could have an adverse effect on our business and results of operations. In the normal course…
New disclosure of material customer concentration risk. Loss of key customers could materially impact revenue and financial condition—a substantive business risk.
The concentration of our customer base could adversely affect our financial condition and operating results. We derive a substantial portion of our revenue from a limited number of customers. The…
Added specific PFAS regulation risk with concrete examples (EU, US states). Escalates from generic environmental compliance to identified regulatory threat requiring material product reformulation.
Our operations must comply with environmental statutes and regulations, and any failure to comply could result in extensive costs which would harm our business. The manufacturing of some of our…
Added specific GLP-1 example and oral delivery threat, escalating from generic risk to concrete competitive pressure in high-growth market segment.
Industry Risks Our sales and profitability are largely dependent on the sale of drug products delivered by injection and the packaging of drug products. If the drug products developed by our…
New explicit disclosure of tariff risk and countermeasures. Prior year omitted tariffs; current year adds them as material trade risk factor.
We are a global company with significant revenues and earnings generated internationally, which exposes us to the impact of foreign currency fluctuations and tariffs, as well as political and…
West Pharmaceutical Services issued a press release on July 23, 2026 announcing second-quarter 2026 financial results, including net sales of $872.3 million (up 13.8%), diluted EPS of $2.15 (up 18.1%), and adjusted-diluted EPS of $2.37 (up 28.8%), along with raised full-year 2026 guidance for net sales and EPS.
View raw filing on EDGAR →West Pharmaceutical entered into amended and restated technology exchange, cross-license, and distributorship agreements with Daikyo Seiko, Ltd. effective July 14, 2026. These are material commercial agreements governing technology sharing, licensing rights, and distribution arrangements for pharmaceutical packaging products with a 10-year term. While the agreements are substantially similar to prior versions, the formal amendment and restatement of these foundational commercial relationships constitutes a material operational event that does not fit the specific categories of M&A activity, debt issuance, or other defined financial/legal events.
View raw filing on EDGAR →Michel Lagarde was appointed as President and Chief Executive Officer effective August 31, 2026, and appointed to the Board of Directors, replacing retiring CEO Eric M. Green. The filing also discloses compensatory arrangements for Mr. Lagarde as part of this executive succession event.
View raw filing on EDGAR →